71 related articles for article (PubMed ID: 18243687)
1. Role of homologous recombination in trabectedin-induced DNA damage.
Tavecchio M; Simone M; Erba E; Chiolo I; Liberi G; Foiani M; D'Incalci M; Damia G
Eur J Cancer; 2008 Mar; 44(4):609-18. PubMed ID: 18243687
[TBL] [Abstract][Full Text] [Related]
2. Homologous recombination but not nucleotide excision repair plays a pivotal role in tolerance of DNA-protein cross-links in mammalian cells.
Nakano T; Katafuchi A; Matsubara M; Terato H; Tsuboi T; Masuda T; Tatsumoto T; Pack SP; Makino K; Croteau DL; Van Houten B; Iijima K; Tauchi H; Ide H
J Biol Chem; 2009 Oct; 284(40):27065-76. PubMed ID: 19674975
[TBL] [Abstract][Full Text] [Related]
3. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Liu XJ; Nowak B; Wang YQ; Plunkett W
Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks.
Hawtin RE; Stockett DE; Wong OK; Lundin C; Helleday T; Fox JA
Oncotarget; 2010 Nov; 1(7):606-619. PubMed ID: 21317456
[TBL] [Abstract][Full Text] [Related]
5. Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background.
Chiappa M; Guffanti F; Grasselli C; Panini N; Corbelli A; Fiordaliso F; Damia G
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474294
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells.
Loi M; Salvatore G; Aquilano M; Greto D; Talamonti C; Salvestrini V; Melica ME; Valzano M; Francolini G; Sottili M; Santini C; Becherini C; Campanacci DA; Mangoni M; Livi L
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430780
[TBL] [Abstract][Full Text] [Related]
7. From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds.
De Sanctis R; Jacobs F; Benvenuti C; Gaudio M; Franceschini R; Tancredi R; Pedrazzoli P; Santoro A; Zambelli A
Front Pharmacol; 2022; 13():909566. PubMed ID: 36160422
[TBL] [Abstract][Full Text] [Related]
8. DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination.
Merlini A; Centomo ML; Ferrero G; Chiabotto G; Miglio U; Berrino E; Giordano G; Brusco S; Pisacane A; Maldi E; Sarotto I; Capozzi F; Lano C; Isella C; Crisafulli G; Aglietta M; Dei Tos AP; Sbaraglia M; Sangiolo D; D'Ambrosio L; Bardelli A; Pignochino Y; Grignani G
Front Oncol; 2022; 12():844250. PubMed ID: 36110934
[TBL] [Abstract][Full Text] [Related]
9. Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines.
Subtil FSB; Gröbner C; Recknagel N; Parplys AC; Kohl S; Arenz A; Eberle F; Dikomey E; Engenhart-Cabillic R; Schötz U
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804930
[TBL] [Abstract][Full Text] [Related]
10. DNA repair and damage pathways in mesothelioma development and therapy.
Malakoti F; Targhazeh N; Abadifard E; Zarezadeh R; Samemaleki S; Asemi Z; Younesi S; Mohammadnejad R; Hadi Hossini S; Karimian A; Alemi F; Yousefi B
Cancer Cell Int; 2022 May; 22(1):176. PubMed ID: 35501851
[TBL] [Abstract][Full Text] [Related]
11. Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant
Chiappa M; Guffanti F; Anselmi M; Lupi M; Panini N; Wiesmüller L; Damia G
Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406579
[TBL] [Abstract][Full Text] [Related]
12. Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment.
Allavena P; Belgiovine C; Digifico E; Frapolli R; D'Incalci M
Front Oncol; 2022; 12():851790. PubMed ID: 35299737
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center.
Hindi N; Carrasco García I; Sánchez-Camacho A; Gutierrez A; Peinado J; Rincón I; Benedetti J; Sancho P; Santos P; Sánchez-Bustos P; Marcilla D; Encinas V; Chacon S; Muñoz-Casares C; Moura D; Martin-Broto J
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322663
[TBL] [Abstract][Full Text] [Related]
14. Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts.
Guffanti F; Alvisi MF; Caiola E; Ricci F; De Maglie M; Soldati S; Ganzinelli M; Decio A; Giavazzi R; Rulli E; Damia G
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847049
[TBL] [Abstract][Full Text] [Related]
15. Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets.
Pereira RB; Evdokimov NM; Lefranc F; Valentão P; Kornienko A; Pereira DM; Andrade PB; Gomes NGM
Mar Drugs; 2019 Jun; 17(6):. PubMed ID: 31159480
[TBL] [Abstract][Full Text] [Related]
16. Platinum Resistance in Ovarian Cancer: Role of DNA Repair.
Damia G; Broggini M
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669514
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.
Uboldi S; Craparotta I; Colella G; Ronchetti E; Beltrame L; Vicario S; Marchini S; Panini N; Dagrada G; Bozzi F; Pilotti S; Galmarini CM; D'Incalci M; Gatta R
BMC Cancer; 2017 Feb; 17(1):107. PubMed ID: 28166781
[TBL] [Abstract][Full Text] [Related]
19. Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
Romano M; Della Porta MG; Gallì A; Panini N; Licandro SA; Bello E; Craparotta I; Rosti V; Bonetti E; Tancredi R; Rossi M; Mannarino L; Marchini S; Porcu L; Galmarini CM; Zambelli A; Zecca M; Locatelli F; Cazzola M; Biondi A; Rambaldi A; Allavena P; Erba E; D'Incalci M
Br J Cancer; 2017 Jan; 116(3):335-343. PubMed ID: 28072764
[TBL] [Abstract][Full Text] [Related]
20. The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
Guffanti F; Fruscio R; Rulli E; Damia G
Sci Rep; 2016 Dec; 6():38142. PubMed ID: 27905519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
